Document Detail


28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen.
MedLine Citation:
PMID:  20191426     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The JPMorgan Healthcare conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Forest Laboratories Inc and Icagen Inc. Investigational drugs from Forest Laboratories, including roflumilast (in collaboration with Nycomed Inc/Mitsubishi Tanabe Pharma Corp), ceftaroline fosamil (with AstraZeneca plc), linaclotide (with Ironwood Pharmaceuticals Inc/Astellas Pharma Inc/Almirall Prodesfarma SA), cariprazine (with Gedeon Richter Ltd/Mitsubishi Tanabe Pharma Corp), aclidinium bromide (with Almirall), dutogliptin (with Phenomix Corp/Chiesi Farmaceutici SpA) and levomilnacipran (with Pierre Fabre SA), and from Icagen, including ICA-105665, are discussed.
Authors:
Sophie Gale; Gary Croasdell
Related Documents :
12602216 - The carl o. boucher prosthodontic conference spans four decades.
20666716 - Meetings and courses calendar.
20665976 - The quality of reporting and publication status of vaccines trials presented at veterin...
20802466 - International society of urological pathology (isup) consensus conference on handling a...
21570746 - The first catalan neurological societies and their protagonists.
3262446 - Consultation with directors of who collaborating centres on influenza: memorandum from ...
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  IDrugs : the investigational drugs journal     Volume:  13     ISSN:  2040-3410     ISO Abbreviation:  IDrugs     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-01     Completed Date:  2010-05-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883655     Medline TA:  IDrugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  145-8     Citation Subset:  IM    
Affiliation:
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sophie.gale@thomsonreuters.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Bacterial Agents / therapeutic use
Antipsychotic Agents / therapeutic use
Drug Evaluation, Preclinical
Drug Industry*
Drugs, Investigational / therapeutic use*
Gastrointestinal Agents / therapeutic use
Humans
Hypoglycemic Agents / therapeutic use
Potassium Channel Blockers / therapeutic use
Respiratory System Agents / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antipsychotic Agents; 0/Drugs, Investigational; 0/Gastrointestinal Agents; 0/Hypoglycemic Agents; 0/Potassium Channel Blockers; 0/Respiratory System Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  28th Annual JPMorgan Healthcare Conference - Affymax and Infinity Pharmaceuticals.
Next Document:  High-Content Analysis - CHI's Seventh Annual Conference - Developments in HCA and Pathway Analysis.